Striatonigral degeneration is a neurological disorder caused by a disruption in the connection between two areas of the brain-the striatum and the substantia nigra. These two areas work together to enable balance and movement. Striatonigral degeneration is a type of multiple system atrophy (MSA). Symptoms of the disorder resemble some of those seen in Parkinson's disease, including rigidity, instability, impaired speech, and slow movements.
There is no cure for striatonigral degeneration, and treatments for the disorder have variable success. Treatments used for Parkinson's disease are recommended. However, unlike Parkinson's disease, striatonigral degeneration is not responsive to levodopa. Dopamine and anticholinergics provide some benefit. Generally, treatment is reevaluated as the disorder progresses.
Striatonigral degeneration progresses slowly. Some patients have normal life expectancy.
The NINDS supports and conducts research on disorders of the brain and nervous system such as striatonigral degeneration. This research focuses on finding ways to prevent and treat these disorders. Information from the National Library of Medicine’s MedlinePlusDegenerative Nerve System
American Parkinson Disease Association
135 Parkinson Avenue
Staten Island, NY 10305-1425
Seeks to “Ease the Burden – Find the Cure” through funding scientific research. Provides comprehensive patient/caregiver support and education.
Parkinson's Action Network (PAN)
Grand Central Station, P.O. Box 4777
New York City, NY 10063-4777
Policy arm of the Michael J. Fox Foundation for Parkinson's Research
New York, NY 10018
Provides research, patient services, clinical studies, public and professional education, and physician referrals at over 60 locations and through a nationwide network of chapters and support groups.
Information sourced through CNF’s partnership with The National Institute of Neurological Disorders and Stroke (NINDS), US National Institutes of Health.